Literature DB >> 7914106

Breast cancer: prognostic significance of c-erb-B2 and int-2 amplification compared with DNA ploidy, S-phase fraction, and conventional clinicopathological features.

U Lönn1, S Lönn, B Nilsson, B Stenkvist.   

Abstract

The prognostic value of oncogene amplification and conventional clinicopathological features was determined in consecutive breast cancers detected during 5 months in 1975-1976 in 4 Swedish counties. Material was collected from 162 of the 179 patients and tumor size, nodal status, FSH, estrogen/progesterone receptor status, DNA ploidy and S-phase fraction determined. Tissues remaining from 80 patients were stored frozen until 1991, when amplification of the oncogenes c-erb-B2 and int-2 was determined. We show that c-erb-B2 amplification (but not int-2 amplification) and positive axillary nodal status show prognostic significance for both survival and relapse-free survival in univariate and multivariate analysis. The other examined factors showed no significance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7914106     DOI: 10.1007/bf00666477

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  33 in total

1.  In Reply: Amplification c-erbB-2 and Aggressive Human Breast Tumors?

Authors:  D J Slamon; G M Clark
Journal:  Science       Date:  1988-06-24       Impact factor: 47.728

2.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

3.  Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation.

Authors:  M Tal; C R King; M H Kraus; A Ullrich; J Schlessinger; D Givol
Journal:  Mol Cell Biol       Date:  1987-07       Impact factor: 4.272

4.  Sequence organization of the human int-2 gene and its expression in teratocarcinoma cells.

Authors:  S Brookes; R Smith; G Casey; C Dickson; G Peters
Journal:  Oncogene       Date:  1989-04       Impact factor: 9.867

5.  Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.

Authors:  H Tsuda; S Hirohashi; Y Shimosato; T Hirota; S Tsugane; H Yamamoto; N Miyajima; K Toyoshima; T Yamamoto; J Yokota
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

6.  HER-2/neu oncogene protein and prognosis in breast cancer.

Authors:  A K Tandon; G M Clark; G C Chamness; A Ullrich; W L McGuire
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

7.  Image cytometry in malignancy grading of breast cancer. Results in a prospective study with seven years of follow-up.

Authors:  B Stenkvist; E Bengtsson; O Eriksson; T Jarkrans; B Nordin
Journal:  Anal Quant Cytol Histol       Date:  1986-12       Impact factor: 0.302

Review 8.  Follow-up study of HER-2/neu amplification in primary breast cancer.

Authors:  G M Clark; W L McGuire
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

9.  Analysis of reproducibility of subjective grading systems for breast carcinoma.

Authors:  B Stenkvist; S Westman-Naeser; J Vegelius; J Holmquist; B Nordin; E Bengtsson; O Eriksson
Journal:  J Clin Pathol       Date:  1979-10       Impact factor: 3.411

10.  Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction.

Authors:  K E Noonan; C Beck; T A Holzmayer; J E Chin; J S Wunder; I L Andrulis; A F Gazdar; C L Willman; B Griffith; D D Von Hoff; I B Roninson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

View more
  2 in total

1.  Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients.

Authors:  Praveen Ravishankaran; R Karunanithi
Journal:  World J Surg Oncol       Date:  2011-02-06       Impact factor: 2.754

2.  A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer.

Authors:  R Michalides; P Hageman; H van Tinteren; L Houben; E Wientjens; R Klompmaker; J Peterse
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.